Genetic Signatures : Company presentation

onlyuse

ersonalCompany Presentation - 1H FY22

FEBRUARY 2022

Disclaimer

InvestorDOCUMENTPresentationTITLE

SEPTEMBERFebruary 20212

This presentation has been prepared by Genetic Signatures Limited ACN 095 913 205 (the Company or GSS) and approved by the Board of Directors for release. It comprises written materials/slides for a verbal presentation concerning the Company and should be read in that context. This presentation is proprietary to GSS. It may not be reproduced, disseminated, quoted or referred to, in whole or in part, without express consent of GSS.

onlyNo representation or warranty, express or implied, is or will be made in relation to, and no responsibility or liability (whether for negligence, under statute or otherwise) is or will be accepted by the Company or by any of its officers, directors, shareholders, employees or advisers as to or in relation to the accuracy or completeness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or any omission from this presentation or of any other written or oral information or opinions provided now or in the future to any interested party or its advisers. In particular, no representation or warranty is given as to the achievement or reasonableness of any plans, future projections, management targets, prospects or returns and nothing in this presentation is or should be relied upon as a promise or representation as to the future.

The Company expressly disclaims all liability for any loss or damage of whatsoever kind (whether foreseeable or not) which may arise from any person acting on any information and opinions relating to the Company contained in this presentation or any information which is made available in connection with any further enquiries, notwithstanding any negligence, default or lack of care. In furnishing this presentation, the Company undertakes no obligation to provide any additional information.

useSubject to any continuing obligation under applicable law or relevant listing rules of the ASX, the Company disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements in these materials to reflect any change in expectations in relation to any forward-looking statements or any change in events, conditions or circumstances on which any statement is based. Nothing in these materials shall under any circumstances create an implication that there has been no change in the affairs of the Company since the date of the presentation.

This presentation is for information purposes only and does not constitute or form part of any offer or invitation to acquire, sell or otherwise dispose of, or issue, or any solicitation of any offer to sell or otherwise dispose of, purchase or subscribe for, any securities, nor does it constitute investment advice, nor shall it or any part of it nor the fact of its distribution form the basis of, or ersonal

be relied on in connection with, any or contract or investment decision. Without limiting the foregoing, this presentation does not constitute an offer to sell, or a solicitation of an offer to buy, ny securities in the United States. The securities of Genetic Signatures have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (Securities Act) or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States except in compliance with the registration requirements of the Securities Act and any other applicable securities laws or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws.

The receipt of this presentation by any person and any information contained herein or subsequently communicated to any person is not to be taken as constituting the giving of investment advice by the Company or any other person to any such person. No such person should expect the Company or any of its officers, directors, shareholders, employees or advisers to owe it any duties or responsibilities and should take its own professional advice. The Recipient must rely solely on its own knowledge, investigation, judgement and assessment of the matters which are the subject of this presentation and to satisfy itself as to the accuracy and completeness

2

Company Summary

Established ASX listed developer and manufacturer of molecular (PCR) based test kits for infectious diseases

onlyNovel 3base® technology - changes DNA sequence, detects the most common mutations, rapid,

low cost and accurate

useEasyScreen™ test kits available for sale in most major markets, expanding into EU and USA

1H FY22 sales $21.8m, up 17% pcp

ersonalYoY growth since listing ‒ 4 year CAGR 93%

Profitable, $37.5m cash, no debt ‒ $4.7m profit 1H FY22

Investor Presentation

FEBRUARY 2022

Trusted & Proven Technology

InvestorDOCUMENTPresentationTITLE

SEPTEMBERFEBRUARY 20221

A 'Syndromic Screening' approach allows users to test a broad range of clinically relevant pathogens based

on patient symptoms, helping clinicians make an accurate diagnosis

onlyuse ersonal1.

EasyScreen™ Detection Kits

Simultaneously detect over 20 pathogens from one sample, shortening turnaround from days to hours

Assays for over 100 organisms, including for SARS-CoV-2, but also other disease states

Streamlined universal sample processing kits - common method across all kits

3base® can detect all known COVID variants1

Customers - high throughput labs, hospital groups and private pathology suppliers

Per in-silico analysis conducted by Genetic Signatures

GS-mini	GS1-HT	GS-1000

Financial Summary - Sales

Revenue from sales (A$m)

only										28.3
											5.4
													21.8
use										4.2
											9.4
											8.2
			11.3
ersonal	4.8	7.0								12.4
								10.5
		1.5
		1.8
		1.1
		1.0
		1.2
		1.0	1.5
		FY19	FY20						FY21	1H FY22
					Q1		Q2		Q3		Q4

InvestorDOCUMENTPresentationTITLE

SEPTEMBERFEBRUARY 20221

Continued Strong Revenue Growth

2Q FY22 $9.4m, up 16% on pcp

Strong local demand for SARS-CoV-2 tests

continue due to ongoing outbreaks

International sales teams actively engaged with existing customers to promote broader EasyScreen™ range - European orders received for Enteric range

New instrument placements continue to support future demand for tests

5